Medexus Schedules Third Fiscal Quarter 2025 Conference Call

Rhea-AI Summary

Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has announced its upcoming third fiscal quarter 2025 conference call, scheduled for Thursday, February 6, 2025, at 8:00 am Eastern Time. The company will discuss financial results for the quarter ended December 31, 2024, with financial statements and MD&A expected to be filed after market close on February 5, 2025.

The call will be accessible via toll-free numbers for Canadian and U.S. callers (888-506-0062) and international callers (+1 973-528-0011) using access code 571655. A live webcast will be available on Medexus's corporate website's Investors section. A replay will be accessible until February 13, 2025, through dedicated phone numbers, and the webcast recording will remain available until February 6, 2026.

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 6, 2025 to discuss Medexus's results for its third fiscal quarter ended December 31, 2024. Medexus expects to file its financial statements and MD&A after markets close on February 5, 2025.

To participate in the call, please dial the following numbers:

888-506-0062 (toll-free) for Canadian and U.S. callers
+1 973-528-0011 for international callers

Access code: 571655

A live webcast of the call will be available on the Investors section of Medexus's corporate website or at the following link:

https://www.webcaster4.com/Webcast/Page/2010/51991

A replay of the call will be available approximately one hour following the end of the call through Thursday, February 13, 2025. To access the replay, please dial the following numbers -

877-481-4010 for Canadian and U.S. callers
+1 919-882-2331 for international callers

Conference ID: 51991

A replay of the webcast will be available on the Investors section of Medexus's corporate website until Friday, February 6, 2026.

About Medexus

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. For more information about Medexus and its product portfolio, please see the company's corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.com.

Contacts

Ken d'Entremont | CEO, Medexus Pharmaceuticals
Tel: 905-676-0003 | Email: ken.dentremont@medexus.com

Brendon Buschman | CFO, Medexus Pharmaceuticals
Tel: 416-577-6216 | Email: brendon.buschman@medexus.com

Forward-Looking statements

Certain statements made in this news release contain forward-looking information within the meaning of applicable securities laws (forward-looking statements). The words "anticipates", "believes", "expects", "will", "plans", "potential", and similar words, phrases, or expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words, phrases, or expressions. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions, and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. Medexus cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Material risk factors include, but are not limited to, those set out in Medexus's materials filed with the Canadian securities regulatory authorities from time to time, including Medexus's most recent annual information form and management's discussion and analysis. Accordingly, undue reliance should not be placed on these forward-looking statements, which are made only as of the date of this news release. Other than as specifically required by law, Medexus undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239244

FAQ

When will Medexus (MEDXF) release its Q3 2025 financial results?

Medexus will release its Q3 2025 financial results after market close on February 5, 2025.

What time is Medexus (MEDXF) Q3 2025 earnings conference call?

The earnings conference call is scheduled for Thursday, February 6, 2025, at 8:00 am Eastern Time.

How can investors access Medexus (MEDXF) Q3 2025 earnings call?

Investors can access the call by dialing 888-506-0062 (toll-free for US/Canada) or +1 973-528-0011 (international) with access code 571655, or via webcast on Medexus's corporate website.

How long will the replay of Medexus (MEDXF) Q3 2025 earnings call be available?

The call replay will be available until February 13, 2025, while the webcast replay will be accessible until February 6, 2026.